Background Conventional criteria for tumor progression may not fully reflect the clinical
benefit of immunotherapy or appropriately guide treatment decisions. The phase II …

Background Urinary bladder carcinoma is common in developed settings, and prognosis
may be impacted by lifestyle factors such as excess body weight and diabetes mellitus. The …

Background: Urologists are frequently confronted with questions of urinary bladder cancer
(UBC) patients about what they can do to improve their prognosis. Unfortunately, it is largely …

Background Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …

Background While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L)
setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for …

Background Cisplatin-based combination chemotherapy is the standard treatment of
advanced urinary tract cancer (aUTC), but 50% of patients are ineligible for cisplatin …

Abstract Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-
infiltrating immune cells (IC) correlated in several studies with PD-L1/programmed death-1 …

Background To investigate the impact of marital status on overall survival (OS) and create a
prognostic nomogram predicting OS in distant-metastatic bladder cancer (DMBC) patients …

Background There is currently no established model for predicting the recurrence of
hepatocellular carcinoma (HCC) in patients with negative alpha‐fetoprotein (AFP) after …

Objective: The aim of this study was to develop and validate a reliable nomogram to
estimate overall survival in bladder cancer. Method: Patients diagnosed with bladder cancer …